

The BJBMS publishes an "Advanced online" manuscript format as a free service to authors in order to expedite the dissemination of scientific findings to the research community as soon as possible after acceptance following peer review and corresponding modification (where appropriate). An "Advanced online" manuscript is published online prior to copyediting, formatting for publication and author proofing, but is nonetheless fully citable through its Digital Object Identifier (doi®). Nevertheless, this "Advanced online" version is NOT the final version of the manuscript. When the final version of this paper is published within a definitive issue of the journal with copyediting, full pagination, etc. the new final version will be accessible through the same doi and this "Advanced online" version of the paper will disappear.

**RESEARCH
ARTICLE**

**NEW AND EMERGING
MEDICAL ENTITIES**

Nimer, et al.: Dietary supplements and COVID-19

The impact of vitamin and mineral supplements usage prior to COVID-19 infection on disease severity and hospitalization

Refat Nimer^{1*}, Omar Khabour¹, Samer Swedan¹, Hassan Kofahi¹

¹Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Jordan

***Corresponding author:** Refat Nimer, PhD, Department of Medical Laboratory Sciences, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan

E-mail: rmnimer@just.edu.jo

DOI: <https://doi.org/10.17305/bjbms.2021.7009>

Submitted: 31 January 2022/**Accepted:** 19 February 2022/**Published online:** 28 February 2022

Conflict of interests: Authors declare no conflict of interests.

Funding: This study is supported by the deanship of research at Jordan University of Science and Technology (grant number 20210173).

License: © The Author(s) (2022). This work is licensed under a Creative Commons Attribution 4.0 International License.

ABSTRACT

The COVID-19 pandemic has caused a global public health emergency. Nutritional status is suggested to be related to the severity of COVID-19 infection. Herein, we aimed to explore the impact of using vitamin and mineral supplements prior to COVID-19 infection on disease severity and hospitalization. In addition, the prior use of aspirin as an anticoagulant on the disease severity was investigated. A cross-sectional, self-administered survey was conducted between March and July 2021. Recovered COVID-19 individuals (age ≥ 18 years, n = 2148) were recruited in the study. A multivariate logistic regression was used to evaluate the associations of supplements and aspirin use with COVID-19 disease severity and hospitalization status. Among the participants, 12.1% reported symptoms consistent with severe COVID-19, and 10.2% were hospitalized due to COVID-19. After adjustment for confounding variables (age, gender, BMI, cigarette smoking status, and the number of comorbidities), the multivariate logistic regression model showed that the consumption of vitamin D supplements prior to COVID-19 infection was associated with a significant decrease in disease severity (OR = 0.68, 95% CI 0.50 - 0.92; P = 0.01), and a lower risk of hospitalization (OR = 0.64, 95% CI 0.45 - 0.89; P = 0.01). On the other hand, there were no significant differences in the frequencies of severe illness and hospitalizations with the consumption of vitamin A, folic acid, vitamin B12, vitamin B complex, vitamin C, zinc, iron, selenium, calcium, magnesium, omega 3, and aspirin before COVID-19 infection. Among the investigated nutrients, the use of vitamin D prior to COVID-19 infection was associated with reduced disease severity and hospitalization. However, more studies are required to confirm this finding.

KEYWORDS: COVID-19; supplements; vitamin D; hospitalization; severity.

INTRODUCTION

The coronavirus disease (COVID-19) is a worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2). According to the WHO, a total of 271,963,258 COVID-19 cases and 5,331,019 deaths were reported as of December 17th, 2021 (3). SARS-CoV-2 infection is associated with a broad spectrum of symptoms ranging from moderate to severe pneumonia, coagulopathy, and death (4). The percentage of severe cases requiring hospitalization varies from country to country but is estimated to account for 10-20% of all SARS-CoV-2 infections globally (5, 6).

Dietary immunomodulators are substances that affect the functions of the immune system. Examples include vitamins A, C, D, E, and beta-carotene, as well as microelements such as zinc, selenium, and omega-3 fatty acids (7, 8). These substances are essential for acquired and innate immunity mediated by neutrophils, macrophages, natural killer cells, and T lymphocytes (7, 9, 10). Therefore, deficiency in dietary immunomodulators could increase the risk of severe COVID-19 infection (11). Such deficiencies can be corrected by following a healthy diet combined with the proper use of supplements. Although the use of vitamin and mineral supplements does not prevent infection with COVID-19 (12), it can improve immune status and subsequent disease severity (13, 14). Hence, the use of supplements has increased drastically during the COVID-19 pandemic (15).

Since COVID-19 has been shown to cause blood clotting, the use of aspirin has increased during the pandemic to overcome such complications. In addition to preventing clotting, aspirin reduces blood levels of interleukin-6 (IL-6), C-reactive protein, and macrophage colony-stimulating factor (16). Therefore, aspirin use may help in reducing the occurrence of COVID-19-induced thrombosis and cytokine storm (17).

Several studies have reported the benefits of using vitamin and mineral supplements following a diagnosis of COVID-19 to improve the clinical course of the disease (18-21). However, the benefits of regular intake of supplements prior to COVID-19 infection on the clinical course remain undefined. The study aimed to investigate the effect of regular use of supplements and aspirin prior to COVID-19 infection on disease severity and hospitalization status. We hypothesize that using some of these dietary supplements would be associated with reduced disease severity and fewer hospitalizations.

MATERIALS AND METHODS

Study design and participants

This study is part of the Jordanian COVID 19 survey project (JCSP). Ethical approval for the project was obtained from the institutional review board of Jordan University of Science and Technology (Ref.: 3/139/2021, dated: 30/03/2021). This cross-sectional study was conducted in Jordan between March and July 2021. The target population were individuals (≥ 18 years old) who recovered from COVID-19 disease. The exclusion criteria included current COVID-19 infections and pre-infection vaccination status. Subjects who had been vaccinated prior to infection were excluded because vaccination strongly influences disease severity and thus may obliterate any effect that could be observed when supplementation was used.

The study instrument

The study utilized a self-administered questionnaire in the Arabic language. The questionnaire collected information from participants on their demographics (such as age, gender, body mass index [BMI], and education), comorbidities, consumption of supplements (vitamins and minerals) and aspirin use prior to infection. In addition, information about disease symptoms and hospitalization status was collected. The questionnaire was face validated by a group of experts

in the field and was piloted on a small sample of the population. Comments were obtained from experts and participants and were used to review and improve the clarity of the questionnaire. Data from the pilot study were not included in the final analyses.

Sampling procedure

The study followed a convenient sampling procedure. The questionnaire was prepared and administered using Google forms. To ensure anonymity, identifying information such as participants' names and places of work were not collected. The first part of the questionnaire obtained informed consent and confirmed recovery from COVID-19. To ensure that the Jordanian population is well represented, trained research assistants recruited participants from different Jordanian governorates and assisted the participants in filling out the questionnaire. A total of 2148 participants completed the questionnaire.

COVID-19 severity classification

Disease symptoms were utilized to classify COVID-19 into two categories as previously reported (22); severe and non-severe (asymptomatic, mild symptoms, and moderate). Mild cases included fever, sore throat, malaise, body pains, nausea, and other symptoms, but no signs or symptoms of pneumonia. Moderate cases included pneumonia (persistent fever and cough) but no hypoxemia ($\text{SpO}_2 \leq 92\%$). Severe cases were assigned to those with verified severe pneumonia and hypoxemia (22). It is worth noting that some severe cases were not admitted to hospitals, which may be due to hospital overcrowding during the peak waves of the COVID-19. Therefore, such cases obtained medical care at home via private doctor visits, and some used medical oxygen supply systems at their homes.

Statistical analysis

The independent variables in the study were the use of supplements and aspirin. The dependent variables were COVID-19 severity and hospitalization. Frequencies and percentages were used for categorical variables. Means and standard deviations (SD) were used for continuous variables. The chi-square was used to test differences in the severity/hospitalization between supplement/aspirin usage groups. Multivariate logistic regression analysis was used to explore the effect of supplement/aspirin usage on the severity/hospitalization after adjustment for possible confounders (age, gender, BMI, cigarette smoking, and number of comorbidities). The adjusted odds ratios (OR) and 95% confidence intervals (CI) were reported for each independent variable. A P value less than 0.05 was considered significant. The data were analyzed using the Statistical Package for the Social Sciences version 23 (IBM Inc., Armonk, New York, United States).

RESULTS

Characteristics of study participants

Overall, 2148 individuals participated in the study. Table 1 summarizes participants' characteristics. Females represented 58.2% of the study population. The mean age \pm SD of the participants was 40 ± 16 years. Among the participants, 12.1% reported symptoms consistent with severe COVID-19, 10.2% were admitted to the hospital due to COVID-19, 23.1% had at least one comorbidity, and 16.9% were current cigarette smokers (Table 1).

Association of supplements and aspirin use with COVID-19 severity and hospitalization

The effects of supplements or aspirin use on the frequencies of COVID-19 severe cases and hospitalizations were investigated (Table 2). Among the supplements included in our study, consumption of vitamin D prior to COVID-19 infection was significantly associated with decreased frequencies of severe illness ($P = 0.04$) and hospitalization ($P = 0.03$). Additionally, the rate of hospitalization was significantly decreased among the participants who consumed vitamin

C before COVID-19 infection ($P = 0.03$). Vitamin C consumption was also associated with reduced disease severity. However, the difference did not reach statistical significance ($P = 0.07$). Moreover, a significantly higher frequency of severe illness and/or hospitalization was observed among participants who consumed selenium, omega 3, vitamin B complex, calcium, and magnesium supplements, and aspirin before COVID-19 infection (Table 2). On the other hand, there were no significant differences in the frequencies of severe illness and hospitalizations with the consumption of vitamin A, folic acid, vitamin B12, multivitamins, zinc, and iron before COVID-19 infection.

Logistic regression analyses

Next, to verify the associations above, we performed multivariate logistic regression analyses to control for the possible confounders such as age, gender, BMI, cigarette smoking, and the number of comorbidities. The ORs and 95% CI for the two outcomes, COVID-19 severity, and hospitalization status with use of each supplement/aspirin, are presented in Table 3. The results of this model demonstrated that after adjusting for the confounders, vitamin D consumption was the only predictive factor to associate with lower risk of COVID-19 severity (OR = 0.68, 95% CI 0.50 - 0.92; $P = 0.01$, Table 3), and lower percentage of hospitalizations (OR = 0.63, 95% CI 0.45 - 0.89; $P = 0.01$, Table 3).

DISCUSSION

In this study, we investigated the impact of using vitamin and mineral supplements and aspirin prior to infection with COVID-19 on disease severity and hospitalization. Previous studies and clinical trials have focused on the impact of using vitamins and minerals during the infection on COVID-19 outcomes (14, 23, 24). These studies reported significant effects of several vitamins and trace elements on reducing disease severity (25-27). However, using these supplements prior

to COVID-19 infection can give a powerful boost to the immune system. This increases its effectiveness in the early stages of the disease and could be crucial in determining disease outcome.

In a large survey of 349,598 participants in the UK, vitamin D levels were negatively associated with the probability of COVID-19 infection. After adjusting for confounders in multivariable analyses, this connection was not maintained (28). In contrast, a large cohort study (n = 108,343) in Spain showed that people with serum vitamin D levels ≥ 30 ng/ml were more likely to have better COVID-19 outcomes after adjusting for outcome variables. (29). In our study, univariate analysis indicated associations between vitamin D and vitamin C consumption and reduced disease COVID-19 severity and hospitalization. However, using regression analysis to adjust for possible confounding factors, only vitamin D consumption was predicted to decrease the risk of severe disease and hospitalization. This indicates that confounding factors likely affected the observed association for vitamin C. Hemilä et al. reported that routine vitamin C supplementation is not justified and fails to reduce the incidence of colds and other respiratory infections (30). Our findings are consistent with Demir et. al., who showed that high vitamin D levels might reduce COVID-19 hospital stay and disease severity (31). Lower vitamin D levels in COVID-19 patients compared to uninfected individuals were reported previously, suggesting a link between inadequate vitamin D levels and susceptibility to infection (32, 33). Additionally, increased infection, hospitalization, and death from COVID-19 has been associated with low vitamin D levels. (34-36). Vitamin D has also been shown to increase the production of anti-inflammatory cytokines, such as IL-10, which is predicted to lower the severity of COVID-19 (37), and improve the activity of macrophages and T lymphocytes (38).

With the exception of vitamin D, adequate amounts of vitamins are obtained through the diet in most individuals (39, 40). However, according to US National Health and Nutrition

Examination Survey (NHANES), about half of the respondents (n = 6,261) did not get sufficient vitamin D from food alone, including fortified products (41). In addition, individuals with darker skin produce less vitamin D than those with lighter skin upon sun exposure (42). Thus, vitamin D supplementation is necessary for maintaining optimal vitamin D levels. In agreement with our results, a meta-analysis of 25 studies with 11,321 participants in total found that vitamin D supplementation significantly reduced the risk of acute respiratory tract infections (43). Furthermore, a meta-analysis conducted by Martineau et al. reported that vitamin D supplementation is associated with protection against acute respiratory infections (43). Therefore, vitamin D supplementation is recommended during the infection with COVID-19, as well as before the infection as a preventative measure (44).

A significantly higher frequency of severe illness and hospitalization was observed among selenium users, omega 3, vitamin B complex, calcium and magnesium supplements and aspirin. However, none of these supplements were predicted to increase the risk of severity/hospitalization in the logistic regression analyses. This discrepancy can be explained by regular usage of these supplements/aspirin is more frequent among individuals with a higher risk for severe illness such as the elderly and those with pre-existing medical conditions (45, 46). Therefore, controlling for these confounding factors is essential to demonstrate true associations between vitamins, minerals, and aspirin and either disease severity or hospitalization status. Consistent with this conclusion, aspirin intake was not associated with COVID-19-related complications and mortality (47). Currently, there is no direct evidence to indicate that omega-3 helps in the defense against COVID-19 (48).

Furthermore, logistic regression analysis indicated no association between B vitamins, calcium, and magnesium intake and COVID-19 severity. It is known that B vitamins regulate

chemokine and cytokine production and mediate the interplay between immune cells involved in pathological processes (49). However, the role of B vitamins in reducing COVID-19 severity is highly controversial (50, 51). Similarly, the role of calcium and magnesium body status in COVID-19 manifestations is still controversial (52-54). It is important to note that the use of supplements such as selenium, vitamin A, and folic acid was too low among the study participants. Therefore, more studies are needed to confirm the present findings.

Although this study assessed the impact of using aspirin and supplements prior to COVID-19 infection on disease severity and hospitalization based on a relatively large sample, it had some limitations. This was a cross-sectional study conducted using an anonymous questionnaire. The findings given were largely self-reported and were dependent on the participants' reliability, honesty, and recallability. It is likely that some participants answered the questions in a way that they believed was objectively appropriate and not entirely correct. Some participants gave extreme responses based on their personal beliefs introducing so response biases.

Previous literature has shown that the severity of COVID-19 is elevated among the elderly, malnourished individuals, and those with high BMI or comorbidities (55-57). Therefore, a regression analysis was applied to control for potential confounding factors in the current study. However, it is recommended that the relationship between supplement use and severity be examined in each subgroup with adequate samples in future studies. Among the limitations of the current investigation is that the study did not collect information regarding duration of illness and time of hospitalization. Therefore, the study could not examine the effect of supplement use on such measures. This could be the subject of future investigations. Furthermore, each participant's rate of supplementary support during the infection was not equal. Also, the levels of supplements and minerals used by the patients were unknown. Finally, since the study is questionnaire-based,

fatal cases (that represent the highest severity) cannot be included. Thus, more clinical studies are needed to confirm the present findings we are proposing within this study.

CONCLUSION

In conclusion, our findings showed that vitamin D supplementation has protective effects against the severity and hospitalization of COVID-19 infection. Therefore, during this pandemic, persons at increased risk of vitamin D insufficiency should consider taking vitamin D supplements to maintain circulating vitamin D at an optimum range.

ACKNOWLEDGMENT

The authors would like to acknowledge the deanship of research at Jordan University of Science and Technology for funding this project (grant number 20210173).

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *New England journal of medicine*. 2020.
2. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. *Jama*. 2020;323(8):709-10.
3. (WHO) WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [cited 2021 December 17]. Available from: <https://covid19.who.int/>.
4. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *Jama*. 2020;324(8):782-93.
5. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*. 2020;20(6):669-77.

6. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *bmj*. 2020;369.
7. Polak E, Stępień AE, Gol O, Tabarkiewicz J. Potential Immunomodulatory Effects from Consumption of Nutrients in Whole Foods and Supplements on the Frequency and Course of Infection: Preliminary Results. *Nutrients*. 2021;13(4).
8. Bae M, Kim H. The Role of Vitamin C, Vitamin D, and Selenium in Immune System against COVID-19. *Molecules*. 2020;25(22):5346.
9. Xia X, Zhang X, Liu M, Duan M, Zhang S, Wei X, et al. Toward improved human health: efficacy of dietary selenium on immunity at the cellular level. *Food & Function*. 2021;12(3):976-89.
10. Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. *J Nutr*. 2003;133(5 Suppl 1):1457s-9s.
11. Im JH, Je YS, Baek J, Chung M-H, Kwon HY, Lee J-S. Nutritional status of patients with COVID-19. *International Journal of Infectious Diseases*. 2020;100:390-3.
12. Speakman LL, Michienzi SM, Badowski ME. Vitamins, supplements and COVID-19: a review of currently available evidence. *Drugs Context*. 2021;10.
13. Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, et al. Role of vitamins and minerals as immunity boosters in COVID-19. *Inflammopharmacology*. 2021;29(4):1001-16.
14. Razeghi Jahromi S, Moradi Tabriz H, Togha M, Ariyanfar S, Ghorbani Z, Naeeni S, et al. The correlation between serum selenium, zinc, and COVID-19 severity: an observational study. *BMC Infectious Diseases*. 2021;21(1):899.

15. Aysin E, Urhan M. Dramatic Increase in Dietary Supplement Use During Covid-19. *Current Developments in Nutrition*. 2021;5(Supplement_2):207-.
16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-4.
17. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thromb Res*. 2020;191:148-50.
18. Shakoor H, Feehan J, Mikkelsen K, Al Dhaheri AS, Ali HI, Platat C, et al. Be well: A potential role for vitamin B in COVID-19. *Maturitas*. 2021;144:108-11.
19. Toscano G, de A, II, de Souza TA, Barbosa Mirabal IR, de Vasconcelos Torres G. Vitamin C and D supplementation and the severity of COVID-19: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2021;100(26):e26427.
20. Wessels I, Rolles B, Rink L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. *Front Immunol*. 2020;11:1712.
21. Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY. The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis. *Clin Epidemiol Glob Health*. 2021;12:100883.
22. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J*. 2021;97(1147):312-20.
23. Güven M, Gültekin H. The effect of high-dose parenteral vitamin D3 on COVID-19-related in-hospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study. *European Journal of Clinical Nutrition*. 2021;75(9):1383-8.

24. Al Sulaiman K, Aljuhani O, Saleh KB, Badreldin HA, Al Harthi A, Alenazi M, et al. Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study. *Scientific Reports*. 2021;11(1):17648.
25. Joachimiak MP. Zinc against COVID-19? Symptom surveillance and deficiency risk groups. *PLoS neglected tropical diseases*. 2021;15(1):e0008895.
26. Alexander J, Tinkov A, Strand TA, Alehagen U, Skalny A, Aaseth J. Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. *Nutrients*. 2020;12(8):2358.
27. Moghaddam A, Heller RA, Sun Q, Seelig J, Cherkezov A, Seibert L, et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. *Nutrients*. 2020;12(7):2098.
28. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr*. 2020;14(4):561-5.
29. Oristrell J, Oliva JC, Casado E, Subirana I, Domínguez D, Toloba A, et al. Vitamin D supplementation and COVID-19 risk: a population-based, cohort study. *J Endocrinol Invest*. 2022;45(1):167-79.
30. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. *Cochrane database of systematic reviews*. 2013(1).
31. Demir M, Demir F, Aygun H. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. *J Med Virol*. 2021;93(5):2992-9.
32. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PloS one*. 2020;15(9):e0239252.

33. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. *JAMA network open*. 2020;3(9):e2019722-e.
34. De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality. *Am J Clin Pathol*. 2021;155(3):381-8.
35. Katz J, Yue S, Xue W. Increased risk for COVID-19 in patients with vitamin D deficiency. *Nutrition*. 2021;84:111106.
36. Seal KH, Bertenthal D, Carey E, Grunfeld C, Bikle DD, Lu CM. Association of Vitamin D Status and COVID-19-Related Hospitalization and Mortality. *J Gen Intern Med*. 2022:1-9.
37. McGregor R, Chauss D, Freiwald T, Yan B, Wang L, Nova-Lamperti E, et al. An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19. *bioRxiv*. 2020:2020.07.18.210161.
38. Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. *Immunology*. 2011;134(2):123-39.
39. Russell R, Beard JL, Cousins RJ, Dunn JT, Ferland G, Hambidge K, et al. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. A Report of the Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine. 2001.

40. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? *J Steroid Biochem Mol Biol*. 2014;144 Pt A:138-45.
41. Orces C, Lorenzo C, Guarneros JE. The Prevalence and Determinants of Vitamin D Inadequacy among U.S. Older Adults: National Health and Nutrition Examination Survey 2007-2014. *Cureus*. 2019;11(8):e5300.
42. Springbett P, Buglass S, Young AR. Photoprotection and vitamin D status. *Journal of Photochemistry and Photobiology B: Biology*. 2010;101(2):160-8.
43. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *bmj*. 2017;356.
44. Abdulateef DS, Rahman HS, Salih JM, Osman SM, Mahmood TA, Omer SHS, et al. COVID-19 severity in relation to sociodemographics and vitamin D use. *Open Med (Wars)*. 2021;16(1):591-609.
45. Bruyère O, Cavalier E, Souberbielle J-C, Bischoff-Ferrari HA, Beudart C, Buckinx F, et al. Effects of vitamin D in the elderly population: current status and perspectives. *Archives of Public Health*. 2014;72(1):32.
46. Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y. Benefits of Vitamins in the Treatment of Parkinson's Disease. *Oxidative Medicine and Cellular Longevity*. 2019;2019:9426867.
47. Son M, Noh MG, Lee JH, Seo J, Park H, Yang S. Effect of aspirin on coronavirus disease 2019: A nationwide case-control study in South Korea. *Medicine (Baltimore)*. 2021;100(30):e26670.

48. Darwesh AM, Bassiouni W, Sosnowski DK, Seubert JM. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? *Pharmacology & Therapeutics*. 2021;219:107703.
49. Huang S, Wei JC, Wu D, Huang Y. Vitamin B 6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. *European journal of clinical nutrition*. 2010;64(9):1007-13.
50. Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B(12) in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). *Nutrition (Burbank, Los Angeles County, Calif)*. 2020;79-80:111017.
51. Wee AKH. COVID-19's toll on the elderly and those with diabetes mellitus - Is vitamin B12 deficiency an accomplice? *Medical hypotheses*. 2021;146:110374.
52. Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. 2021;9(1):149-56.
53. Ebrahimzadeh-Attari V, Panahi G, Hebert JR, Ostadrahimi A, Saghafi-Asl M. Nutritional approach for increasing public health during pandemic of COVID-19: A comprehensive review of antiviral nutrients and nutraceuticals. 2021;11(2):119-36.
54. Pinnawala NU, Thrastardottir TO, Constantinou C. Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19. 2021;10(3):200-10.
55. Li Y, Zhu C, Zhang B, Liu L, Ji F, Zhao Y, et al. Nutritional status is closely related to the severity of COVID-19: a multi-center retrospective study. *Journal of infection in developing countries*. 2021;15(4):490-500.

56. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. *Obesity research & clinical practice*. 2020;14(4):295-300.
57. Lauc G, Sinclair D. Biomarkers of biological age as predictors of COVID-19 disease severity. *Aging (Albany NY)*. 2020;12(8):6490-1.

TABLES AND FIGURES WITH LEGENDS

TABLE 1: Baseline characteristics of the participants.

Characteristic	Value
Number of participants	2148
Age (years; Mean \pm SD)	40 \pm 16
Gender	
Male (n, %)	903 (42.0%)
Female (n, %)	1245 (58.0%)
BMI (Mean \pm SD)	28.17 \pm 7.38
Cigarette smokers (n, %)	362 (16.9%)
Comorbidities (n, %)	496 (23.1%)
Disease severity (n, %)	
Severe	260 (12.1%)
Non-severe	1888 (87.9%)
Hospitalization status (n, %)	
Hospitalized	219 (10.2%)
Not hospitalized	1929 (89.8%)

TABLE 2: Severe COVID-19 and hospitalization cases according to use of supplements and substances prior to infection.

Supplement/substance taken before COVID-19		COVID Classification					Hospitalized				
		Non-severe		Severe		P value	No		Yes		P value
		n	%	n	%		n	%	n	%	
Vitamin C	No	1303	87.0	194	13.0	0.07	1330	88.8	167	11.2	0.03
	Yes	585	89.9	66	10.1		599	92.0	52	8.0	
Vitamin A	No	1761	87.9	243	12.1	0.91	1800	89.8	204	10.2	0.93
	Yes	127	88.2	17	11.8		129	89.6	15	10.4	
Vitamin D	No	1173	86.8	179	13.2	0.04	1199	88.7	153	11.3	0.03
	Yes	715	89.8	81	10.2		730	91.7	66	8.3	
Omega 3	No	1585	88.4	207	11.6	0.08	1620	90.4	172	9.6	0.04
	Yes	303	85.1	53	14.9		309	86.8	47	13.2	
Folic acid	No	1694	87.5	241	12.5	0.13	1732	89.5	203	10.5	0.17
	Yes	194	91.1	19	8.9		197	92.5	16	7.5	
Multivitamins	No	1507	87.6	213	12.4	0.43	1545	89.8	175	10.2	0.95
	Yes	381	89.0	47	11.0		384	89.7	44	10.3	
B complex vitamins	No	1729	88.3	229	11.7	0.06	1768	90.3	190	9.7	0.02
	Yes	159	83.7	31	16.3		161	84.7	29	15.3	
Vitamin B12	No	1533	87.5	220	12.5	0.18	1569	89.5	184	10.5	0.33
	Yes	355	89.9	40	10.1		360	91.1	35	8.9	
Zinc	No	1608	88.3	214	11.7	0.23	1644	90.2	178	9.8	0.12
	Yes	280	85.9	46	14.1		285	87.4	41	12.6	
Calcium	No	1680	88.3	223	11.7	0.13	1720	90.4	183	9.6	0.01
	Yes	208	84.9	37	15.1		209	85.3	36	14.7	
Magnesium	No	1769	88.2	236	11.8	0.08	1810	90.3	195	9.7	0.01
	Yes	119	83.2	24	16.8		119	83.2	24	16.8	
Iron	No	1557	87.6	220	12.4	0.39	1593	89.6	184	10.4	0.59
	Yes	331	89.2	40	10.8		336	90.6	35	9.4	
Selenium	No	1843	88.1	248	11.9	0.04	1884	90.1	207	9.9	0.01
	Yes	45	78.9	12	21.1		45	78.9	12	21.1	
Aspirin	No	1559	90.6	162	9.4	0.00	1585	92.1	136	7.9	0.00
	Yes	329	77.0	98	23.0		344	80.6	83	19.4	

TABLE 3: Logistic regression analyses for supplements and aspirin use with COVID-19 severity and hospitalization as the output.

Supplement/substance taken before COVID- 19	Total number of users	Severity			Hospitalization		
		P	OR	95% CI	P	OR	95% CI
Vitamin C	651	0.18	0.81	0.59-1.11	0.08	0.73	0.51-1.04
Vitamin A	144	0.36	0.77	0.43-1.36	0.40	0.77	0.42-1.41
Vitamin D	796	0.01**	0.68	0.50-0.92	0.001**	0.64	0.45-0.89
Omega 3	356	0.43	1.15	0.81-1.65	0.30	1.23	0.83-1.80
Folic acid	213	0.16	0.69	0.40-1.17	0.23	0.70	0.39-1.26
Vitamin B complex	190	0.69	1.10	0.70-1.74	0.40	1.23	0.76-2.00
Vitamin B12	395	0.06	0.70	0.48-1.02	0.15	0.74	0.49-1.11
Zinc	326	0.46	1.15	0.79-1.68	0.21	1.29	0.86-1.93
Calcium	245	0.76	0.94	0.61-1.43	0.40	1.21	0.78-1.88
Magnesium	143	0.73	1.09	0.66-1.81	0.24	1.36	0.81-2.29
Iron	371	0.83	1.04	0.70-1.55	0.37	1.22	0.79-1.88
Selenium	57	0.80	1.10	0.54-2.26	0.48	1.30	0.62-2.71
Aspirin	427	0.28	1.20	0.86-1.66	0.08	0.96	0.67-1.37

Each independent variable was adjusted for age, gender, BMI, cigarette smoking status, and the number of comorbidities. **p ≤0.01; *p ≤0.05.